How long does Nintedanib treatment need to be taken and the course of treatment instructions

Nintedanib (Nintedanib) is an oral small molecule multi-target tyrosine kinase inhibitor that mainly inhibits vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor It can achieve anti-fibrosis and anti-tumor effects through signaling pathways such as sub-receptor (FGFR) and platelet-derived growth factor receptor (PDGFR). The drug was developed by Boehringer Ingelheim in Germany and has been approved in many countries around the world. It is widely used to treat idiopathic pulmonary fibrosis (IPF), systemic sclerosis-related interstitial lung disease (SSc-ILD), chronic interstitial lung disease (ILD), etc. This article will provide a detailed analysis of the treatment time, treatment schedule, clinical practice and patient management of nintedanib.

1. Basic principles and goals of nintedanib treatment

The core role of nintedanib is to delay the progression of pulmonary fibrosis. In diseases such as idiopathic pulmonary fibrosis, lung tissue undergoes an abnormal repair response after being repeatedly damaged, leading to excessive proliferation of fibrous tissue and a gradual decline in lung function. Nintedanib can effectively slow down the decline of lung function and delay the progression of the disease by inhibiting multiple signaling pathways related to fibrosis.

Nintedanib is not intended to "cure" pulmonary fibrosis, but rather as a long-term management drug to "slow the progression of the disease." Therefore, the continuity and stability of its treatment are crucial to its efficacy.

2. Treatment time: long-term, continuous, individualized adjustment

According to the results of global large-scale clinical studies (such asINPULSIS-1 and INPULSIS-2), nintedanib needs to be taken continuously for a long time to achieve clinical effects of delaying the decline of lung function and reducing acute exacerbations. Studies have shown that nintedanib can slow down the annual decline rate of FVC (a measure of lung function) in patients with idiopathic pulmonary fibrosis from about 200ml to about 110ml, and this effect is maintained under the premise of continued medication.

Clinically, the recommended dose of nintedanib is usually 150mg twice daily (once in the morning and once in the evening). In terms of treatment course, doctors generally recommend the strategy of "long-term use and evaluation of follow-up", that is, unless serious adverse reactions occur or the condition significantly improves or worsens, patients need to continue taking it for months to years or even longer**. Some patients have been taking the medicine continuously for more than 5 years and can still achieve stable therapeutic effects.

3. Considerations for discontinuation and adjustment of medication

Although nintedanib emphasizes long-term use, there are situations where medication needs to be adjusted or suspended. Mainly include the following categories of situations:

1.Severe adverse reactions

The most common side effects are gastrointestinal reactions, such as diarrhea, nausea, loss of appetite, etc. If the symptoms are mild, doctors will usually recommend symptomatic treatment (such as the use of antidiarrheal drugs) and continued observation; if the symptoms are severe or affect the quality of life, the dosage may be considered to be reduced to 100 mg twice a day, or even temporarily suspended.

2.Abnormal liver function

Nintedanib can cause an increase in transaminases, so liver function should be checked regularly while taking the drug. If ALT and AST are found to be significantly elevated, it is necessary to suspend the medication and evaluate whether to resume treatment after the liver enzymes recover.

3.The disease progresses obviously or is ineffective

If the patient's condition does not improve or even worsens after several months of continuous use, such as a sharp decline in lung function, an expansion of fibrosis on CT scans, etc., the doctor may evaluate whether to continue using nintedanib or consider switching to other drugs.

Generally speaking, the decision to discontinue medication must be made by a professional doctor based on the comprehensive judgment of the patient's condition and drug tolerance, and patients should not discontinue medication on their own.

4. Treatment course management suggestions and patient precautions

Nintedanib treatment involves long-term follow-up and comprehensive management. Here are some suggestions:

1.Adhere to long-term treatment and avoid interruptions

Significant improvement may not be felt in the early stages of the disease, but the real effect of nintedanib is to "delay" the disease rather than "reverse" it. Interrupting medication will weaken the therapeutic effect. Even if symptoms improve, medication should not be stopped at will.

2.Regular review and dynamic evaluation of efficacy

It is recommended that patients undergo pulmonary function tests, routine blood tests and liver function tests every 3-6 months, as well as review high-resolution CT to facilitate doctors to evaluate treatment effects and adjust medication plans.

3.Monitor adverse reactions and communicate with doctors promptly

Common side effects, such as diarrhea, can be relieved by adjusting your diet or using medications such as loperamide. If severe nausea, abnormal liver function, skin allergies, etc. occur, seek medical attention as soon as possible.

4. Cooperate with comprehensive treatment and life management

While taking nintedanib, you should avoid smoking and contact with irritating gases, maintain appropriate exercise (such as pulmonary rehabilitation training), and consume balanced nutrition to help delay the deterioration of lung function.

Nintedanib is a targeted drug used to control the progression of pulmonary fibrosis. The treatment cycle is usually long, with the core goal of “delaying the disease”. Once patients start taking medication, they should continue to use it under the guidance of a professional doctor, undergo regular review and evaluation, and flexibly adjust the medication strategy. Under the premise of good compliance and active cooperation, nintedanib can significantly improve patients' quality of life and long-term prognosis.

For every patient who uses nintedanib, rational arrangement of medication courses, scientific management of side effects, and adherence to long-term treatment are the keys to achieving the best efficacy.

Reference materials:https://www.drugs.com/